Kenvue Inc. (KVUE) Stock: Price, Forecast & Analyst Target
Kenvue Inc. (KVUE) — MoonshotScore 73/100 (Strong band), calculated Oct 26, 2026. Price $19.50 (-0.36%), as of the Oct 26, 2026 trading session; market cap $37.5B. Expected results Nov 2, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 33.78× (market value Oct 26, 2026; cash Jun 28, 2026) · expected results Nov 2, 2026
Kenvue Inc. · KVUE · NYSE · Consumer Defensive · Household & Personal Products
Research dated 2026-09-13: Kenvue sells branded consumer-health products used for pain, allergies, smoking cessation, skin care, oral care, infant care and wounds; Tylenol-led Self Care is its largest reported business. Recent sales have improved from the comparable period, but profit conversion has been uneven, making the key question whether brand demand can lift earnings while a debt-heavy balance sheet limits flexibility.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Kenvue (KVUE)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $3.96B (Q2 FY2026, quarter ended Jun 28, 2026)
- EPS beat 6 of 8
- expected results Nov 2, 2026
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 73 | Strong | |
| 73 | Strong | |
| 72 | Strong | |
| 73 | Strong | |
| 73 | Strong | |
| 73 | Strong |
The score was 73 in the stored Oct 24, 2026 snapshot and remains 73 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Financial Safety +1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $19.50 | |
| Change on the day | -0.36% | |
| 52-week range | $14.02–$20.13 | |
| Market capitalisation | $37.5B | |
| Price / earnings (trailing) | 22.49 | |
| Shares traded on the day | 9.49M | |
| Beta (volatility vs the S&P 500) | 0.45 | |
| Dividends per share (last 12 months) | $1.04 | |
| Dividend yield (last 12 months) | 5.33% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Kenvue (KVUE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 12, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the KVUE film — every key number, told as a short cinematic story
~2 min · open the film
What is Kenvue (KVUE), and what does it report?
Short answer · as of
The household and personal-products classification misses Kenvue’s therapeutic core.
Research dated 2026-09-13.
The household and personal-products classification misses Kenvue’s therapeutic core. Consumers buy Tylenol, Zyrtec and Nicorette for specific health needs, while Neutrogena, Aveeno, Listerine and Band-Aid address skin, hygiene and wound-care routines.
Reported revenue combines Self Care, Essential Health, and Skin Health and Beauty. Self Care contributes the largest sales pool, so the consolidated result measures demand across distinct care occasions rather than a uniform household-goods cycle.
What do the latest results show for Kenvue (KVUE)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $3.96B.
Research dated 2026-09-13.
In the latest comparable period, revenue, gross profit, operating profit and net income all improved. Against the immediately preceding period, however, sales rose while gross profit barely changed and operating profit and net income fell, showing that incremental sales did not translate cleanly through the income statement.
The latest earnings release fell modestly short of analyst expectations for revenue and earnings after earlier releases had cleared those hurdles. Recent annual results tell a related story: revenue declined while net income recovered, and Kenvue disclosed costs tied to exit or disposal activity.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $3.96B Jun 28, 2026
- Latest quarter · SG&A
- $0.00 Jun 28, 2026
- Latest quarter · FMP standardized operating result
- $699.00M Jun 28, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 28, 2026 | $3.96B | Not available | $0.00 | $699.00M |
| Mar 29, 2026 | $3.91B | $84.00M | $1.45B | $855.00M |
| Dec 28, 2025 | $3.78B | Not available | $1.53B | $825.00M |
| Sep 28, 2025 | $3.76B | Not available | $1.51B | $629.00M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.96B Aug 6, 2026
- Latest report · revenue estimate
- $3.97B Aug 6, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 6, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | $3.96B | $3.97B | $0.3100 | $0.3187 |
| May 7, 2026 | $3.91B | $3.84B | $0.3200 | $0.2621 |
| Feb 17, 2026 | $3.78B | $3.69B | $0.2700 | $0.2227 |
| Nov 3, 2025 | $3.76B | $3.82B | $0.2800 | $0.2602 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3.96B | $456M | $0.24 (diluted) |
| Q1 FY2026 | $3.91B | $474M | $0.25 (diluted) |
| Q4 FY2025 | $3.78B | $330M | $0.17 (diluted) |
| Q3 FY2025 | $3.76B | $398M | $0.21 (diluted) |
What are the financial strengths and risks for Kenvue (KVUE)?
Short answer
Cash and short-term investments were $1.11B at the Jun 28, 2026 balance-sheet date. Operating cash flow was $688.00M for the quarter ended Jun 28, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow has remained positive across the displayed periods, though generation swings materially. Cash and short-term investments have stayed fairly stable and recently edged higher, but debt greatly exceeds that liquidity, while near-term coverage ratios leave little cushion.
The dividend has continued and was recently raised slightly, so cash must support shareholder distributions alongside capital spending and debt service. A setback in Self Care or renewed pressure between gross profit and operating profit would matter disproportionately because the largest segment supports a capital structure with limited liquid offset.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $688.00M Jun 28, 2026
- Previous quarter · operating cash flow
- $489.00M Mar 29, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 28, 2026 | $688.00M | $138.80M |
| Mar 29, 2026 | $489.00M | −$139.00M |
| Dec 28, 2025 | $854.00M | −$110.00M |
| Sep 28, 2025 | $294.00M | −$98.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Kenvue (KVUE)?
Short answer · as of
The next earnings report is expected on Nov 2, 2026.
Research dated 2026-09-13.
Revenue alone will not settle the Kenvue question at the scheduled earnings release. Watch whether gross profit resumes rising with sales, whether operating and net profit recover from their sequential decline, and whether cash generation remains positive without leverage increasing.
Consensus projections assume gradual sales and earnings expansion over later periods. Progress toward that path would look more credible if Self Care remains firm, cash stays stable and finance leadership gains permanence; the scheduled dividend also makes operating cash conversion relevant, not merely accounting earnings.
How does Kenvue compare with its peers?
Short answer
Kenvue's score ranks 3rd of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Relative to a pure beauty or household-products company, Kenvue combines nonprescription remedies with skin care, oral care, infant care, feminine care and wound treatment. That mix ties sales to ailments and replenishment routines as well as beauty demand.
Self Care is the largest business, while Essential Health and Skin Health and Beauty provide meaningful but smaller revenue bases. The distinguishing feature is exposure to several consumer-health occasions under widely recognized brands, not superior growth or profitability established against peers.
| Company | Price | Market value | Score |
|---|---|---|---|
| $12.39 Oct 26, 2026 | $27.5B | 95 5-pillar Oct 26, 2026 | |
| $168.23 Oct 26, 2026 | $33.8B | 74 5-pillar Oct 26, 2026 | |
| Kenvue (KVUE) — this page | $19.50 | $37.5B | 73 |
| $82.16 Oct 26, 2026 | $40.4B | 70 5-pillar Oct 26, 2026 | |
| $80.14 Oct 23, 2026 | $38.6B | 62 5-pillar Oct 26, 2026 | |
| $34.68 Oct 23, 2026 | $47.2B | 46 5-pillar Oct 26, 2026 | |
| $109.63 Date unavailable | $36.5B | — Model unavailable | |
| $108.85 Date unavailable | $39.4B | — Model unavailable | |
| $105.38 Date unavailable | $25.0B | — Model unavailable | |
| $94.04 Date unavailable | $75.0B | — Model unavailable | |
| $63.51 Date unavailable | $14.6B | — Model unavailable | |
| $86.40 Date unavailable | $10.5B | — Model unavailable | |
| $66.23 Date unavailable | $143B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $19.00 – $20.00
- Consensus target
- $19.50
- Median target
- $19.50
Consensus record · Captured .
Measured against a quoted price of $19.50 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 2, 2026
- Transactions
- 39
- Identified insiders
- 19
- Purchases
- 0
- Sales
- 2
- Other transactions
- 37
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 95.2% Period end Jun 30, 2026
- Previous quarter · ownership
- 91.1% Prior to period end Jun 30, 2026
- Reporting holders
- 1,040 Period end Jun 30, 2026
- Previous quarter · holders
- 1,054 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 157,051,418 |
| Blackrock, INC. | 150,825,694 |
| Vanguard Capital Management LLC | 125,314,564 |
| State Street Corp | 121,619,054 |
| Vanguard Portfolio Management LLC | 93,303,762 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What Investors Ask About Kenvue (KVUE) — Consumer Defensive
Research dated 2026-09-13; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why does Tylenol matter so much to Kenvue?
Tylenol sits within Self Care, Kenvue’s largest segment by revenue. That makes demand for pain relief and other nonprescription remedies more consequential to companywide sales than the household-products classification suggests.
Can Neutrogena and Aveeno offset weakness in Kenvue Self Care?
Neutrogena and Aveeno belong to Skin Health and Beauty, which has a smaller revenue base than Self Care. Offsetting material Self Care weakness would therefore require growth large enough to overcome the segment-size gap.
What role do Listerine and Band-Aid play inside Kenvue?
Listerine and Band-Aid sit in Essential Health alongside infant, feminine and wound-care products. The segment broadens Kenvue beyond medicines and beauty while contributing a revenue base between its other reported businesses.
Does Kenvue’s dividend fit with its debt and cash generation?
Recurring positive operating cash flow supports the dividend, which was recently raised slightly. Debt remains far above cash and short-term investments, so cash conversion and leverage matter to the durability of that distribution.
What is the KVUE stock price today?
The last price recorded on this page for Kenvue Inc. (KVUE) is $19.50, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the KVUE price target?
The analyst consensus price target for Kenvue Inc. (KVUE) is $19.50 (range $19.00 to $20.00, median $19.50), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are KVUE's next earnings?
The next earnings date listed on this page for Kenvue Inc. (KVUE) is Nov 2, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (80 figures)
The 80 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Summit, NJ | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1 Kenvue Way, Summit, NJ, 07901, US". The FMP company description names Skillman, New Jersey as the headquarters; this page uses the address in this row. |
FMP — 70 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $19.50 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T21:54:31.636Z. | |
px.change | Change on the day | -0.36% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $37.5B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:02.000Z. Captured from FMP at 2026-10-26T21:54:30.692Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.07 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $3.96B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $14.02–$20.13 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 22.49 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 9.49M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.45 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Kirk L. Perry | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 21,890 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $15.05B, net result $2.08B; FY2022 revenue $14.95B, net result $2.06B; FY2023 revenue $15.44B, net result $1.66B; FY2024 revenue $15.46B, net result $1.03B; FY2025 revenue $15.12B, net result $1.47B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Self Care $6.38B · Essential Health $4.63B · Skin Health and Beauty $4.11B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 58.2% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-28.revenue_k | Revenue — period end 2026-06-28 | $3.96B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.sga_k | SG&A — period end 2026-06-28 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.operating_result_k | FMP standardized operating result — period end 2026-06-28 | $699.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.revenue_k | Revenue — period end 2026-03-29 | $3.91B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.rd_k | R&D — period end 2026-03-29 | $84.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.sga_k | SG&A — period end 2026-03-29 | $1.45B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.operating_result_k | FMP standardized operating result — period end 2026-03-29 | $855.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.revenue_k | Revenue — period end 2025-12-28 | $3.78B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.sga_k | SG&A — period end 2025-12-28 | $1.53B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-28.operating_result_k | FMP standardized operating result — period end 2025-12-28 | $825.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.revenue_k | Revenue — period end 2025-09-28 | $3.76B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.sga_k | SG&A — period end 2025-09-28 | $1.51B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.operating_result_k | FMP standardized operating result — period end 2025-09-28 | $629.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.revenue_actual | Revenue · reported — report date 2026-08-06 | $3.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $3.97B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | $0.3100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | $0.3187 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $3.91B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $3.84B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | $0.3200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | $0.2621 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_actual | Revenue · reported — report date 2026-02-17 | $3.78B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.revenue_estimated | Revenue · estimate — report date 2026-02-17 | $3.69B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_actual | EPS · reported — report date 2026-02-17 | $0.2700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_estimated | EPS · estimate — report date 2026-02-17 | $0.2227 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_actual | Revenue · reported — report date 2025-11-03 | $3.76B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.revenue_estimated | Revenue · estimate — report date 2025-11-03 | $3.82B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_actual | EPS · reported — report date 2025-11-03 | $0.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-03.eps_estimated | EPS · estimate — report date 2025-11-03 | $0.2602 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.11B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $688.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-28. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $8.48B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 3.56× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-28.operating_cash_flow_m | Operating cash flow — period end 2026-06-28 | $688.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-29.operating_cash_flow_m | Operating cash flow — period end 2026-03-29 | $489.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-28.capex_m | Capital expenditure (reported) — period end 2026-06-28 | $138.80M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-29.capex_m | Capital expenditure (reported) — period end 2026-03-29 | −$139.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-28.operating_cash_flow_m | Operating cash flow — period end 2025-12-28 | $854.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-28.capex_m | Capital expenditure (reported) — period end 2025-12-28 | −$110.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.operating_cash_flow_m | Operating cash flow — period end 2025-09-28 | $294.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.capex_m | Capital expenditure (reported) — period end 2025-09-28 | −$98.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $19.00 – $20.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $19.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $19.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 39 transactions · 0 purchases, 2 sales, 37 other transactions · 19 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Oct 2, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 95.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 91.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 1,040 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 1,054 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 157,051,418 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 150,825,694 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Capital Management LLC — shares in provider snapshot | 125,314,564 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | State Street Corp — shares in provider snapshot | 121,619,054 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 93,303,762 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 2, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-08-29 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-12 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 33.78× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.11B at Jun 28, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-06-28. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.04 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 5 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-26, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 5.33% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-06.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($3.96B) with the recorded estimate ($3.97B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.3100) with the recorded estimate ($0.3187) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 73 of 100 · Strong · pillars 81 / 53 / 40 / 67 / 79 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 73 (stored snapshot Oct 24, 2026) → 73 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-28. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-28.revenue_k,fin.q_table.depth.2026-06-28.sga_k,fin.q_table.depth.2026-06-28.operating_result_k,fin.q_table.depth.2026-03-29.revenue_k,fin.q_table.depth.2026-03-29.rd_k,fin.q_table.depth.2026-03-29.sga_k,fin.q_table.depth.2026-03-29.operating_result_k,fin.q_table.depth.2025-12-28.revenue_k,fin.q_table.depth.2025-12-28.sga_k,fin.q_table.depth.2025-12-28.operating_result_k,fin.q_table.depth.2025-09-28.revenue_k,fin.q_table.depth.2025-09-28.sga_k,fin.q_table.depth.2025-09-28.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_actual,earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.revenue_actual.comparison,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-17.revenue_actual,earn.history.depth.2026-02-17.revenue_estimated,earn.history.depth.2026-02-17.eps_actual,earn.history.depth.2026-02-17.eps_estimated,earn.history.depth.2025-11-03.revenue_actual,earn.history.depth.2025-11-03.revenue_estimated,earn.history.depth.2025-11-03.eps_actual,earn.history.depth.2025-11-03.eps_estimated. - Cash-flow note. Source series as of 2026-06-28. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-28.operating_cash_flow_m,fin.opcf.depth.2026-03-29.operating_cash_flow_m,fin.opcf.depth.2026-06-28.capex_m,fin.opcf.depth.2026-03-29.capex_m,fin.opcf.depth.2025-12-28.operating_cash_flow_m,fin.opcf.depth.2025-12-28.capex_m,fin.opcf.depth.2025-09-28.operating_cash_flow_m,fin.opcf.depth.2025-09-28.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Kenvue Inc. | 2026-02-20 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-20 |
| Business description | Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Self Care: $6.38B; Essential Health: $4.63B; Skin Health and Beauty: $4.11B | 2025-12-28 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Cash, investments and debt | Total debt: $8.48B; Liquidity basis: cash and short-term investments; Total liabilities: $16.18B; Cash and short-term investments: $1.11B; Cash and investments: $1.11B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Sector / industry (provider taxonomy) | Consumer Defensive / Household & Personal Products The company's SEC filings classify it under SIC 2844 — Perfumes, Cosmetics & Other Toilet Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-06 | FMP | Financial Modeling Prep (FMP) earnings |
| Recent SEC filings |
| 2026-08-06 | OFFICIAL | SEC EDGAR filer submissions |
| Most recent periodic reports | Annual: Document: https://www.sec.gov/Archives/edgar/data/1944048/000194404826000030/kvue-20251228.htm, Filed: 2026-02-20, Period end: 2025-12-28; Quarterly: Document: https://www.sec.gov/Archives/edgar/data/1944048/000194404826000142/kvue-20260628.htm, Filed: 2026-08-06, Period end: 2026-06-28 | 2026-08-06 | OFFICIAL | SEC EDGAR filer submissions |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.11B; Cash and short-term investments: $1.11B; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-28 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-28; Cash basis: cash and short-term investments; Net cash: -$7.37B; Total debt: $8.48B; Cash and investments: $1.11B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-28 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.71; Current ratio: 1.01; Debt to equity: 0.8; Net margin: 10.8%; Gross margin: 58.2%; Operating margin: 19.5%; Return on assets: 6.2%; Return on equity: 15.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-08-12 | FMP | Financial Modeling Prep (FMP) dividend history |
| Next scheduled dividend | Ex date: 2026-09-21; Declared on: 2026-09-10; Record date: 2026-09-21; Payment date: 2026-10-02; Amount per share: $0.21 Amount is per share as declared, before any withholding. Owning the share before the ex-date is what carries entitlement. | 2026-09-10 | FMP | Financial Modeling Prep (FMP) dividend calendar |
| Next earnings report | Date: 2026-11-02; EPS estimate: $0.28 per share; Revenue estimate: $3.86B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Named officers | CEO: Kirk L. Perry; Officers: Michael Wondrasch — Title: Chief Technology & Data Officer, Pay: $1.02M, Born: 1969; Caroline Tillett — Title: Chief Scientific Officer, Born: 1972; Anil Agarwal — Title: Head of Total Rewards; Jonathan Halvorson — Title: Chief Digital & Marketing Officer, Born: 1983; Matthew Orlando — Title: General Counsel, Pay: $1.25M, Born: 1977; Heather R. Howlett — Title: Interim CFO & Chief Accounting Officer, Born: 1978; Kirk L. Perry — Title: Chief Executive Officer & Director, Pay: $2.94M, Born: 1967; Sofya Tsinis — Title: Head of Investor Relations Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
Data provided for informational purposes only.